Keywords: fda, extends, review, wyeth, first-in-class, mtor, inhibitor

FDA extends review on Wyeth's first-in-class mTOR inhibitor, Torisel, in advanced renal cell carcinoma

Article | 16 April 2007

Print This

US drug major Wyeth Pharmaceuticals says that the Food and Drug Administration has extended the review of the New Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in